StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > Q1 2021 Financials /Operational update

<< Previous

Bullboard Posts

Next >>

Comment by kodiakupon May 17, 2021 8:59pm

104 Views

Post# 33219059

RE:RE:RE:RE:RE:RE:Q1 2021 Financials /Operational update

- I don't know where you see 7 million in banks when they have 0.08 / loss shares ...for the last quarter.....

Financial Overview

For the fiscal year ended 31 December 2020,StageZero Life Sciences Ltd revenues increased from $139Kto $4.2M. Net loss increased 97% to $6.9M. Revenues reflectan increase in demand for the Company's products andservices due to favorable market conditions. Higher netloss reflects Salaries and short-term benefits increase of18% to $1.7M (expense), Rent increase of 26% to $14K(expense).

Employees:	51 as of Dec 31, 2020

Reporting Currency:	U.S. Dollars
Enterprise value:	$37.91M as of Dec 31, 2020
Annual revenue (TTM):	$5.02M as of Dec 31, 2020
EBITDA (TTM):	-$3.70M as of Dec 31, 2020
Net annual income (TTM):	-$8.31M as of Dec 31, 2020
Free cash flow (TTM):	-$3.80M as of Dec 31, 2020
Net Debt Last Fiscal Year:	N/A
Shares outstanding:	60,247,857 as of May 3, 2021